+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of long-term use of sorafenib: final report of a phase Ii trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma



Efficacy and safety of long-term use of sorafenib: final report of a phase Ii trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma



European Journal of Cancer Suppl.s 7(2): 437-438




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067144509

Download citation: RISBibTeXText

DOI: 10.1016/s1359-6349(09)71480-6


Related references

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. Bju International 108(11): 1813-1819, 2011

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Investigational new Drugs 30(3): 1046-1054, 2012

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Japanese Journal of Clinical Oncology 43(6): 616-628, 2013

Clinical benefits of long-term use of sorafenib in Japanese patients with unresectable renal cell carcinoma (RCC). Journal of Clinical Oncology 26(15_Suppl): 16039-16039, 2016

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clinical Cancer Research 13(6): 1801-1809, 2007

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Annals of Oncology 24(12): 2967-2971, 2013

Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. International Journal of Clinical Oncology 21(1): 126-132, 2016

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer 107: 37-45, 2019

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology 27(20): 3312-3318, 2009

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Japanese Journal of Clinical Oncology 37(10): 755-762, 2007

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. European Journal of Cancer 48(10): 1452-1465, 2012

Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study. Oncology Letters 3(4): 935-939, 2012

Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma. Clinical Genitourinary Cancer 16(6): 437-444.E6, 2018

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. European Journal of Cancer 46(13): 2432-2440, 2010

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 78(5-6): 340-347, 2010